SAN DIEGO , Oct. 19, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to provide information to physicians to improve the diagnosis and treatment of cancer, announces the closing of its previously
Biocept now positioned as the only commercial liquid biopsy provider that offers single-biomarker testing, tumor-specific panels, and circulating tumor cell analysis SAN DIEGO , May 20, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed
Target Selector™ assay kits enable assay developers to leverage Biocept's patented, high-sensitivity technology for the detection of key actional oncogene mutations from both tissue biopsies and blood for liquid biopsy uses SAN DIEGO , April 28, 2020 /PRNewswire/ -- Biocept, Inc .
Patented Blood Collection Tube and Sample Collection Shipping Kit enable the safe transport at room temperature of patient specimens containing both circulating tumor DNA or RNA (ctDNA or ctRNA) and circulating tumor cells (CTCs) SAN DIEGO , Nov. 7, 2019 /PRNewswire/ -- Biocept, Inc.
Biocept Announces Allowance of Key Patent for its Circulating Tumor Cell Platform San Diego, California: ? Biocept, Inc., a privately?held CLIA?certified laboratory testing company, focused on the detection and analysis of circulating tumor cells (CTCs) in blood samples from cancer patients,
SAN DIEGO , Aug. 30, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to provide information to physicians to improve the diagnosis and treatment of cancer, announces a preferred provider agreement with
Biocept's Target Selector™ to be used in profiling and monitoring patients diagnosed with non-small cell lung cancer throughout an integrated healthcare delivery system SAN DIEGO , Aug. 6, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests
Healthcare Group supports more than 50 skilled nursing facilities SAN DIEGO , Aug. 13, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve outcomes, announces it
SAN DIEGO , Feb. 7, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC ), a leading commercial provider of liquid biopsy solutions, announces that it has entered into an agreement with Agiomix FZ-LLC ("Agiomix"), a provider of genomics sample and bioinformatics services to customers around the
Collaboration highlights the power and versatility of the proprietary Switch-Blocker technology, which may be applied to molecular diagnostics in COVID-19 and other infectious diseases, in addition to oncology applications currently commercialized and in development SAN DIEGO , Aug.
